Detail akcie Co-Diagnostics Rg online

Business Summary: Co-Diagnostics, Inc. is a molecular diagnostics company, which develops, manufactures and markets diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious disease. Its diagnostics systems enable dependable, low-cost, molecular testing for organisms and genetic diseases by automating or simplifying historically complex procedures in both the development and administration of tests. It is developing a portable diagnostic device and test system designed for point-of-care and at-home use. The system consists of its PCR instrument that it refers to as the Co-Dx PCR Pro instrument, its proprietary diagnostic test cup system and a mobile application to be installed on the user’s mobile device.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Co-Diagnostics Inc revenues decreased 90% to $359K. Net loss decreased 21% to $21.2M. Revenues reflect United States segment decrease of 90% to $340K, Rest of the world segment decrease of 93% to $19K. Lower net loss reflects Research and development - Balancing val decrease of 12% to $14M (expense), General and administrative - Balancing v decrease of 24% to $5.5M (expense).